|
 In a major legal and regulatory shift cascading across the country, the landmark judgment of the Kerala High Court curbing deceptive discount display boards outside medical shops has emerged as a role model for pharmaceutical trade associations nationwide to push for strict enforcement against unethical retail practices.
Drawing direct inspiration from the judicial precedent established in Kerala, the Retail Distribution Chemists Alliance (RDCA), Delhi has stepped up its advocacy with state regulatory authorities and issued two pivotal advisories to its members, calling for an immediate halt to misleading promotional price hoardings across the National Capital Territory.
The first advisory issued by RDCA outlines a comprehensive framework on retail margins, discount boards, and authorized sourcing aimed at maintaining supply chain integrity and public interest. Reiterating established trade practices and regulatory norms, the alliance highlighted that retail margins under the Drug Prices Control Order (DPCO) and National Pharmaceutical Pricing Authority (NPPA) framework are capped at 16 per cent for scheduled formulations, while non-scheduled formulations typically carry a 20 per cent margin. The advisory emphasized that arbitrary price cuts offered beyond normal trade margins must be scrutinized, warning consumers that heavy discounts alone do not guarantee product safety or genuine quality, and advising them to verify invoice authenticity, batch details, and manufacturing credentials.
In its second circular issued on August 8 titled 'Official Legal Awareness Advisory to Members', RDCA explicitly instructed all retail members to avoid displaying discount boards featuring exaggerated, ambiguous, or misleading price claims. Grounded in the legal precedent set by the Kerala High Court, the trade body called upon medical store operators to conduct an immediate audit of their storefronts and remove non-compliant promotional displays.
Speaking on the campaign, RDCA president Sandeep Nangia emphasized that transparency, responsible sourcing, and compliance with Pharmacy Practice Regulations remain the cornerstone of community pharmacy, adding that trade bodies across various states are mobilizing to replicate this regulatory model to eliminate predatory pricing tactics. The judicial bedrock of this nationwide movement stems from a single-bench verdict of the High Court of Kerala delivered on June 19, 2026, which upheld the statutory power of the Drugs Control Department to mandate sworn undertakings from pharmacy licensees prohibiting deceptive discount hoardings. While recognizing that retail chemists possess the commercial liberty to sell medicines below the Maximum Retail Price (MRP), the court firmly ruled that retailers do not enjoy a legal right to display vague or misleading promotional advertisements to lure vulnerable patients. Following this judicial mandate, state dugs Control department issued a statewide administrative circular instructing enforcement officials to initiate rigorous drives and collect mandatory declarations in Form A and Form B from new applicants and existing license holders.
The legal validity of the regulatory framework was further strengthened when a Division Bench of the High Court of Kerala, comprising Dr Justice A K Jayasankaran Nambiar and Justice Preeta A K, formally closed a subsequent appeal (W.A. No. 1397 of 2026) filed by a discount chain operator as infructuous. The appellate bench noted that with the state DC department issuing a fresh circular incorporating standard affidavit formats, the grievances raised stood redressed while keeping the Single Bench’s substantive ruling on regulatory oversight fully operative. This judicial closure settled legal ambiguities, giving drug controllers in other states a solid basis to act against unverified discount displays.
Welcoming the court directives and subsequent administrative drives, state trade bodies including the All Kerala Chemists and Druggists Association (AKCDA) and regional federations across Maharashtra, Punjab, Tamil Nadu, and Odisha have intensified their crackdown on deep-discounting models offering unrealistic price cuts of 20 to 90 per cent. Retail representatives pointed out that such aggressive rebates are commercially unviable for genuine stock routed through ethical manufacturer-distributor channels without risking quality or sourcing compromises. By establishing clear directives for pharmacy responsibility and joint distributor-retailer vigilance, RDCA has urged all stakeholders to procure stock solely through company-authorized distribution channels.
|